Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?

B. Mungo, D. Molena, M. Stem, Stephen C Yang, Richard J Battafarano, Malcolm V Brock, A. O. Lidor

Research output: Contribution to journalArticle

Abstract

Neoadjuvant therapy has proven to be effective in the reduction of locoregional recurrence and mortality for esophageal cancer. However, induction treatment has been reported to be associated with increased risk of postoperative complications. We therefore compared outcomes after esophagectomy for esophageal cancer for patients who underwent neoadjuvant therapy and patients treated with surgery alone. Using the American College of Surgeons National Surgical Quality Improvement Program database (2005-2011), we identified 1939 patients who underwent esophagectomy for esophageal cancer. Seven hundred and eight (36.5%) received neoadjuvant therapy, while 1231 (63.5%) received no neoadjuvant therapy within 90 days prior to surgery. Primary outcome was 30-day mortality, and secondary outcomes included overall and serious morbidity, length of stay, and operative time. Patients who underwent neoadjuvant treatment were younger (62.3 vs. 64.7, P <0.001), were more likely to have experienced recent weight loss (29.4% vs. 15.9%, P <0.001), and had worse preoperative hematological cell counts (white blood cells 11 × 109/L: 29.3% vs. 15.0%, P <0.001; hematocrit

LanguageEnglish (US)
Pages644-651
Number of pages8
JournalDiseases of the Esophagus
Volume28
Issue number7
DOIs
StatePublished - Oct 1 2015

Fingerprint

Neoadjuvant Therapy
Esophageal Neoplasms
Morbidity
Mortality
Esophagectomy
Operative Time
Quality Improvement
Leukocyte Count
Hematocrit
Weight Loss
Length of Stay
Cell Count
Databases
Recurrence

Keywords

  • Chemotherapy
  • Esophageal cancer
  • Esophagectomy
  • Outcome
  • Radiation therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality? / Mungo, B.; Molena, D.; Stem, M.; Yang, Stephen C; Battafarano, Richard J; Brock, Malcolm V; Lidor, A. O.

In: Diseases of the Esophagus, Vol. 28, No. 7, 01.10.2015, p. 644-651.

Research output: Contribution to journalArticle

@article{9ef435ca1072433085cc8b4875c77326,
title = "Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?",
abstract = "Neoadjuvant therapy has proven to be effective in the reduction of locoregional recurrence and mortality for esophageal cancer. However, induction treatment has been reported to be associated with increased risk of postoperative complications. We therefore compared outcomes after esophagectomy for esophageal cancer for patients who underwent neoadjuvant therapy and patients treated with surgery alone. Using the American College of Surgeons National Surgical Quality Improvement Program database (2005-2011), we identified 1939 patients who underwent esophagectomy for esophageal cancer. Seven hundred and eight (36.5{\%}) received neoadjuvant therapy, while 1231 (63.5{\%}) received no neoadjuvant therapy within 90 days prior to surgery. Primary outcome was 30-day mortality, and secondary outcomes included overall and serious morbidity, length of stay, and operative time. Patients who underwent neoadjuvant treatment were younger (62.3 vs. 64.7, P <0.001), were more likely to have experienced recent weight loss (29.4{\%} vs. 15.9{\%}, P <0.001), and had worse preoperative hematological cell counts (white blood cells 11 × 109/L: 29.3{\%} vs. 15.0{\%}, P <0.001; hematocrit",
keywords = "Chemotherapy, Esophageal cancer, Esophagectomy, Outcome, Radiation therapy",
author = "B. Mungo and D. Molena and M. Stem and Yang, {Stephen C} and Battafarano, {Richard J} and Brock, {Malcolm V} and Lidor, {A. O.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/dote.12251",
language = "English (US)",
volume = "28",
pages = "644--651",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?

AU - Mungo, B.

AU - Molena, D.

AU - Stem, M.

AU - Yang, Stephen C

AU - Battafarano, Richard J

AU - Brock, Malcolm V

AU - Lidor, A. O.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Neoadjuvant therapy has proven to be effective in the reduction of locoregional recurrence and mortality for esophageal cancer. However, induction treatment has been reported to be associated with increased risk of postoperative complications. We therefore compared outcomes after esophagectomy for esophageal cancer for patients who underwent neoadjuvant therapy and patients treated with surgery alone. Using the American College of Surgeons National Surgical Quality Improvement Program database (2005-2011), we identified 1939 patients who underwent esophagectomy for esophageal cancer. Seven hundred and eight (36.5%) received neoadjuvant therapy, while 1231 (63.5%) received no neoadjuvant therapy within 90 days prior to surgery. Primary outcome was 30-day mortality, and secondary outcomes included overall and serious morbidity, length of stay, and operative time. Patients who underwent neoadjuvant treatment were younger (62.3 vs. 64.7, P <0.001), were more likely to have experienced recent weight loss (29.4% vs. 15.9%, P <0.001), and had worse preoperative hematological cell counts (white blood cells 11 × 109/L: 29.3% vs. 15.0%, P <0.001; hematocrit

AB - Neoadjuvant therapy has proven to be effective in the reduction of locoregional recurrence and mortality for esophageal cancer. However, induction treatment has been reported to be associated with increased risk of postoperative complications. We therefore compared outcomes after esophagectomy for esophageal cancer for patients who underwent neoadjuvant therapy and patients treated with surgery alone. Using the American College of Surgeons National Surgical Quality Improvement Program database (2005-2011), we identified 1939 patients who underwent esophagectomy for esophageal cancer. Seven hundred and eight (36.5%) received neoadjuvant therapy, while 1231 (63.5%) received no neoadjuvant therapy within 90 days prior to surgery. Primary outcome was 30-day mortality, and secondary outcomes included overall and serious morbidity, length of stay, and operative time. Patients who underwent neoadjuvant treatment were younger (62.3 vs. 64.7, P <0.001), were more likely to have experienced recent weight loss (29.4% vs. 15.9%, P <0.001), and had worse preoperative hematological cell counts (white blood cells 11 × 109/L: 29.3% vs. 15.0%, P <0.001; hematocrit

KW - Chemotherapy

KW - Esophageal cancer

KW - Esophagectomy

KW - Outcome

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84943660505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943660505&partnerID=8YFLogxK

U2 - 10.1111/dote.12251

DO - 10.1111/dote.12251

M3 - Article

VL - 28

SP - 644

EP - 651

JO - Diseases of the Esophagus

T2 - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 7

ER -